Skip to main content

BBIO BridgeBio Pharma, Inc.

Healthcare

75.00 +0.04 +0.05% Close 11/2
Since 2024-12-02 +181.8%
Open
75.01
High
76.70
Low
74.20
Prev close
74.95
Volume
3.1M
Amplitude
3.34%
Revenue YoY (TTM)
+161.3%
52W 60.22 93.42

Is BridgeBio Pharma, Inc. a buy? Fundamentals and valuation first

As of 2026-10-30

Growth: Good, Risk / liquidity: Good.

Valuation Neutral Free-cash-flow yield is Average.
TTM P/E -24.65 N/A
Price / book -8.78 N/A
Free-cash-flow yield (%) -3.61 35th percentile Average
US Stock Backtest in Python: Price-to-Book Ratio StrategyQuality Factor Investing: A US Quality Value Backtest
Quality Neutral ROE, TTM is Top, but FCF margin, TTM is Lagging.
ROE, TTM (%) 34.3 89th percentile Top
Operating margin, TTM (%) -44.35 18th percentile Lagging
FCF margin, TTM (%) -56.97 17th percentile Lagging
Quality Factor Investing: A US Quality Value Backtest
Growth Good Revenue growth, TTM YoY is Top, but Diluted EPS growth, TTM YoY is Average.
Revenue growth, TTM YoY (%) 161.27 93th percentile Top
Diluted EPS growth, TTM YoY (%) -27.45 43th percentile Average
Momentum Neutral 240-day return is Good, but 60-day return is Average.
60-day return (%) -9.48 43th percentile Average
240-day return (%) 12.89 65th percentile Good
Momentum Trading Strategy: A 12-1 Momentum Backtest
Risk / liquidity Good 20-day dollar volume is Top; 60-day annualized volatility is Good.
20-day dollar volume 190,534,009 92th percentile Top
60-day annualized volatility (%) 32.88 38th percentile Good
Factor Investing Explained: 10 Classic Factors in US Stocks

BridgeBio Pharma, Inc. (BBIO) today

1 quant signals active · As of 2026-10-30

Win rate and excess are historical post-trigger stats vs the market. Click a signal for its full definition and samples; history does not predict future results.

FinLab Studio

From BridgeBio Pharma, Inc. to every stock like it

AI finds several complementary traits of BridgeBio Pharma, Inc. across different dimensions, combines them into a multifactor strategy, and backtests it against the market.

Screen stocks like BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. (BBIO) peers and tracking

Watchlist

This page refreshes daily after the close. Add BridgeBio Pharma, Inc. to your watchlist to track signal changes on your next visit.

BridgeBio Pharma, Inc. (BBIO) quant signal backtests

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

EPS surprise beat

Active · now 22.54%

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

PEAD: Post-Earnings Announcement Drift Backtest
10 historical occurrences (since 2019-11-07)

Average forward return after EPS surprise beat

20-day: Win 44.4%, Sample 9, Median -3.96%, Excess +0.01%, Beat mkt rate 33.3%

60-day: Win 55.6%, Sample 9, Median +10.12%, Excess +4.9%, Beat mkt rate 55.6%

120-day: Win 55.6%, Sample 9, Median +18.63%, Excess +3.97%, Beat mkt rate 55.6%

120 days after: historical avg +9.71%

20-day +0.99%
60-day +9.93%
120-day +9.71%
20-day
60-day
120-day
Win
44.4%
55.6%
55.6%
Sample
9
9
9
Median
-3.96%
+10.12%
+18.63%
Excess
+0.01%
+4.9%
+3.97%
Beat mkt rate
33.3%
55.6%
55.6%

Over 9 occurrences, 120-day forward avg gained 9.71%, beat the market by 3.97 pts; win rate 55.6%.

More history: Market-wide momentum baseline, Signals not active now

Market-wide momentum baseline

Across 99,493 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.42%, a 58.4% positive-return rate, and +3.08 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

11 times historically; 60-day forward avg +10.21%, win rate 63.6%, beating the market by +4.92 pts on average.

Top-quintile 6-month momentum

Pending

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

Momentum Trading Strategy: A 12-1 Momentum Backtest

18 times historically; 60-day forward avg +9.46%, win rate 55.6%, beating the market by +6.34 pts on average.

Filed revenue acceleration

Pending

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

10 times historically; 60-day forward avg -8.41%, win rate 20%, beating the market by -11.26 pts on average.

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.